2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology …
MM Kittleson, GS Panjrath, K Amancherla… - Journal of the American …, 2023 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives
J Reed, S Bain, V Kanamarlapudi - Diabetes, Metabolic Syndrome …, 2021 - Taylor & Francis
Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …
metabolic disease largely characterised by impaired insulin secretion and action. Significant …
[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
Emerging targets in type 2 diabetes and diabetic complications
S Demir, PP Nawroth, S Herzig… - Advanced …, 2021 - Wiley Online Library
Type 2 diabetes is a metabolic, chronic disorder characterized by insulin resistance and
elevated blood glucose levels. Although a large drug portfolio exists to keep the blood …
elevated blood glucose levels. Although a large drug portfolio exists to keep the blood …
GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
R Hammoud, DJ Drucker - Nature Reviews Endocrinology, 2023 - nature.com
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity
DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …